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Identity 
Other names: Venous malformation with glomus cells 
(VMGLOM); Glomangioma; Multiple glomus tumor. 
Note: Glomuvenous malformation (GVM) is a 
localized bluish-purple cutaneous vascular lesion, 
histologically consisting of distended venous channels 
with flattened endothelium surrounded by variable 
number of maldifferentiated smooth muscle-like 
“glomus cells” in the wall. GVM account for 5% of 
venous anomalies referred to centers for vascular 
anomalies. Previously, these lesions have been called 
“multiple glomus tumors” or “glomangioma”. 
Inheritance: GVM is often, if not always, hereditary 
(64%), and transmitted as an autosomal dominant 
disorder. Expressivity varies, as does penetrance, which 
is age dependent and maximal (93%) by 20 years of 
age. 
Clinics 
Phenotype and clinics 
There is a wide phenotypic variation between GVM 
patients, even within the same family (with the same 
germline mutation). An individual can have an 
extensive lesion, affecting for example a whole 
extremity or most of the trunk, while others have 
minor, scattered papulonodular lesions of a few 
millimetres in diameter. The lesions are often multiple, 
and they can affect any body part. 
Seven features characterize GVM lesions :  
(1) Colour: GVMs can be pink in infants, the most are
bluish-purple; 
(2) Affected tissues: the lesions are localized to the skin 
and subcutis, and they are rarely mucosal and never 
extend deeply into muscles; 
(3) Localization: lesions are more often located on the 
extremities, although they can be found all over the
body; 
(4) Appearance: lesions are usually nodular and 
multifocal, raised with a cobblestone-like appearance, 
except for the rare plaque-like variant. They are oft n 
hyperkeratotic; 
(5) The lesions are not compressible; 
(6) The lesions are painful on palpation; 
(7) New lesions can appear with time, likely after 
trauma. 
 
Examples of GVMs: (A) Extended GVM on leg. (B) Small GVM 
on knee. 
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At the histological level, the mural glomus cells are 
positive for smooth muscle alpha-actin and vimentin, 
but negative for desmin, Von Willebrand factor and S-
100. Under electron microscopy, glomus cells show 
smooth muscle myofibrils and “dense bodies”, 
characteristics of vascular smooth muscle cells 
(vSMCs). Thus, these cells are most likely 
incompletely or improperly differentiated vSMCs. 
Neoplastic risk 
GVM has no neoplastic histological characteristics and 
never becomes malignant. 
Treatment 
The gold-standard treatment for GVM consists of 
surgical resection, as lesions are superficial and r rely 
affect deeply the underlying muscle, and sometimes 
sclerotherapy. In contrast to venous malformations, the 
use of elastic compressive garments often aggravate 
pain and should thus be avoided. 
Evolution 
GVM is a developmental lesion that grows 
proportionally with the child. After partial resection, 
recurrence is frequent. New small lesions can appear 
with time. The red plaque-like lesions of the young 
darken with age. 
Cytogenetics 
No cytogenetic abnormally has been reported for 
GVM. 




Description: The glomulin gene spans about 55 kbp and 
contains 19 exons coding for 1785 bp. 
Transcription: 2 kb transcript. 
Protein 
Glomulin was identified by reverse genetics, and its 
function is currently unknown. 
Description: Glomulin gene encodes a protein of 594
amino acids (68 kDa). 
Expression: The high level of glomulin expression in 
the murine vasculature indicates that glomulin may 
have an important role in blood vessel development 
and/or maintenance. 
 
Localisation: Glomulin is likely an intracellular potein. 
Function: The exact function of glomulin is unknown. 
Glomulin has been described to interact with FKBP12, 
an immunophilin that binds the immunosuppressive 
drugs FK506 and rapamycin. FKBP12 interacts with 
the TGFbeta type I receptor, and prevents its 
phosphorylation. Thus, FKBP12 safeguards against the 
ligand-independent activation of this pathway. 
Glomulin, through its interaction with FKBP12, could 
act as a repressor of this inhibition. 
Glomulin has also been described to interact with c-
MET. Glomulin interacts with the inactive, non 
phosphorylated form of c-MET. When c-MET is 
activated by HGF, glomulin is released in a 
phosphorylated form. This leads to p70 S6 protein 
kinase (p70S6K) phosphorylation. It is not known 
whether glomulin activates p70S6K directly or 
indirectly. The p70S6K is a key regulator of protein 
synthesis. Glomulin could thereby control cellular 
events such as migration and cell division. 
The third reported glomulin partner is Cul7. This places 
glomulin in an SCF-like complex, which is implicated 
in protein ubiquitination and degradation. 
Mutations 
There is no phenotype-genotype correlation in GVM. 
Germinal: To date, 29 different inherited mutations 
(deletions, insertions and nonsense substitutions) have 
been identified. The most 5' mutation are located in the 
first coding exon. The majority of them cause 
premature truncation of the protein and likely result in 
loss-of-function. One mutation deletes 3 nucleotides 
resulting in the deletion of an asparagine at position 
394 of the protein. 
More than 70% of GVMs are caused by eight different 
mutations in glomulin: 157delAAGAA (40,7%), 108C 
to A (9,3%), 1179delCAA (8,1%), 421insT and 
738insT (4,65% each), 554delA+556delCCT (3,5%), 
107insG and IVS5-1(G to A) (2,3% each). 
Somatic: The phenotypic variability observed in GVM 
could be explained by the need of a somatic second-hit 
mutation. Such a mechanism was discovered in one 
GVM (somatic mutation 980delCAGAA), suggesting 
that the lesion is due to a complete localized loss-of-
function of glomulin. This concept can explain why 
some patients have bigger lesions than others, why new 
lesions appear, and why they are multifocal. This could 
also explain, why some mutation carriers are 
unaffected. 
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Schematic representation of glomulin : The two stars indicate the start and the stop codons, in exon 2 and 19 respectively. All known 
mutations are shown. Somatic second hit is in blue. 
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